News & Topics

HOME > News & Topics > Research > FY 2018 > Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients (Shohei Koyama (Kumanogoh Group) in JCI insight)

Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients (Shohei Koyama (Kumanogoh Group) in JCI insight)

Shohei Koyama (Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine), Atsushi Kumanogoh (Osaka University Graduate School of Medicine & IFReC), and their research group developed a method for monitoring the state of anti-PD-1 antibody binding to T lymphocytes. They found nivolumab bounds to T lymphocytes for more than 20 weeks even after the last infusion.

Figure1 The change in nivolumab-binding status.
The schematics present three different binding statuses: complete binding, partial binding, and no binding.



Commentary(PDF)


Article (External-Link)


Contact:
Atsushi Kumanogoh

Atsushi Kumanogoh(Immunopathology)


Tel06-6879-3831
Mailkumanogoimed3.med.osaka-u.ac.jp

Immunology Frontier Research Center, Osaka University (WPI-IFReC)

Archives

 
TOPに戻る